Podcasts about Hepatitis C

Zafar Mirza is a Pakistani public health professional who served as the special assistant to the prime minister Imran Khan for Health from 2019 to 2020.The Pakistan Experience is an independently produced podcast looking to tell stories about Pakistan through conversations. Please consider supporting us on Patreon:https://www.patreon.com/thepakistanexperienceTo support the channel:Jazzcash/Easypaisa - 0325 -2982912Patreon.com/thepakistanexperienceAnd Please stay in touch:https://twitter.com/ThePakistanExp1https://www.facebook.com/thepakistanexperiencehttps://instagram.com/thepakistanexpeperienceThe podcast is hosted by comedian and writer, Shehzad Ghias Shaikh. Shehzad is a Fulbright scholar with a Masters in Theatre from Brooklyn College. He is also one of the foremost Stand-up comedians in Pakistan and frequently writes for numerous publications. Instagram.com/shehzadghiasshaikhFacebook.com/Shehzadghias/Twitter.com/shehzad89Join this channel to get access to perks:https://www.youtube.com/channel/UC44l9XMwecN5nSgIF2Dvivg/joinChapters:0:00 Introduction1:00 What happened at PIMS?4:20 Why it happened12:15 Neonatal Mortality in Pakistan18:06 Hepatitis C, Diabetes, HIV and Stunted Growth29:59 Healthcare System has collapsed37:30 Primary Health care and priorities of the Government49:00 Solutions and why Governments keep failing

Brittany recaps Gogo's first day at school and a life changing purchase. Nicole Kidman and Sandra Bullock were on the Today Show talking Practical Magic 2. Lori Loughlin Files for Divorce from Mossimo Giannulli and heads back to court and the Biebers are fine guys!Wayback Wednesday we look back on the record breaking summer in pop culture. Phoebe Bridges is us, the Afflecks are stepping out and Pamala Anderson talks about her scary Hepatitis C diagnosis in the 90s. Gary Oldman says that the new Bond has been chosen and Kendall loves a good heist and tells us about the latest one. It's Hot To Go with Chris Rock, Dianna Russini and Lori Loughlin and Last Call! See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

La Mtra. Claudia Hernández, especialista en salud hepática, profundiza en esta segunda parte de la entrevista sobre los principales retos que representa la hepatitis C en materia de diagnóstico, tratamiento y atención integral en México. Explica que esta infección viral puede permanecer sin síntomas durante largos periodos, lo que dificulta su detección oportuna y favorece la progresión del daño hepático hasta etapas avanzadas, como fibrosis, cirrosis o cáncer de hígado. Esta evolución silenciosa convierte a la enfermedad en un importante problema de salud pública que requiere fortalecer las estrategias de prevención y diagnóstico. A lo largo del programa comenta que uno de los mayores desafíos es garantizar el acceso oportuno al tratamiento.

La Lic. Claudia Hernández, consultora independiente y vocera de la Fundación Mexicana para la Salud Hepática, aborda en esta emisión las características de la hepatitis C, sus formas de transmisión y los desafíos que representa para la salud pública. Explica que la hepatitis es un proceso inflamatorio del hígado que puede tener diversas causas, entre ellas infecciones virales. Señala que, a diferencia de otros tipos de hepatitis, la infección por virus C presenta una alta probabilidad de evolucionar hacia una condición crónica, aumentando el riesgo de desarrollar fibrosis, cirrosis e incluso cáncer hepático. La especialista menciona que la principal vía de transmisión es el contacto con sangre contaminada, situación que puede ocurrir mediante transfusiones antiguas, uso compartido de agujas, procedimientos médicos sin adecuada esterilización o prácticas como tatuajes y perforaciones realizadas en condiciones inseguras. Destaca que uno de los principales retos es su carácter silencioso, ya que muchas personas pueden vivir años sin presentar síntomas.

Dr. Andrew Holman is a rheumatologist and the CEO of Seattle-based Inmedix, which recently received FDA clearance for the first cloud-based heart rate variability (HRV) diagnostic platform. Dr. Holman shares how a “detective” mindset led him from early interests in orthopedics and cardiology into rheumatology, fibromyalgia research, and ultimately entrepreneurship. He explains how chronic stress, the autonomic nervous system, and conditions like sleep apnea and restless leg syndrome can influence cardiovascular risk and autoimmune disease outcomes, and why measuring stress biology with medical-grade precision matters. Dr. Holman also offers hard-earned advice for physician-innovators, reflects on pivotal study results, and shares what he hopes to be remembered for: never dismissing patients in distress.  Guest links: https://www.inmedix.com | https://www.linkedin.com/company/inmedix-inc Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 088 - Andrew Holman [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to be welcoming as my guest Dr. Andrew Holman. Dr. Holman is a rheumatologist and the CEO of Inmedix, a Seattle-based medical diagnostics company that recently received FDA clearance for the first cloud-based heart rate variability diagnostic platform. He has 25 years of clinical experience with 16 peer-reviewed papers and clinical trials demonstrating that measuring stress biology with medical grade precision can improve success rates in autoimmune diseases. All right. Andrew, welcome to the show. I'm so glad you're here today. [00:01:30] Andrew Holman: Yes, happy to be here. Thank you for inviting me. [00:01:33] Lindsey Dinneen: Course, of course. Well, I would love, if you wouldn't mind starting out telling us a little bit about who you are, what your background is, and what led you to medtech. [00:01:44] Andrew Holman: Sure. Well, I'm a, a guy from Seattle, Washington. Grew up here, but trained everywhere else, became a rheumatologist. We study autoimmune diseases, lupus, rheumatoid arthritis. I also was very interested in fibromyalgia and pain. We're the immunologists of medicine. So, I started my practice, golly, a while ago. 1992, I finished my prac- my training, and I was the main rheumatologist at a large suburban hospital at the southern end of Seattle. So hometown, circle back to the hometown. I went into rheumatology because you have many choices when you do internal medicine. You can go be a specialist in many things. But I like the puzzles. The immunology has grown and it's a, it's a particularly sort of detective-oriented specialty. So, I didn't set out to be an entrepreneur. That came 25 years later. I was an in-the-trenches doc trying to help the person in front of me with these devastating diseases that are crippling diseases, usually of young women mostly. [00:02:45] Lindsey Dinneen: Yeah. Okay, and I'm sure there's, there's much more we're gonna dive into, but one thing that really stood out really fast was you, you kind of called yourself a detective, which I really love that term. And so I'm curious, is that something that you always thought you wanted to specialize in, in medicine, or was this, you know, detectiving to come later? Was this something that, you know, you ended up learning more about while in med school and thought, "Oh, this sounds really cool. I could put really two interesting passions together"? [00:03:19] Andrew Holman: Yeah, it was-- you know, things just sort of come into play sometime. For those who are not in medicine, they may not realize it takes about ten years to go to college, med school, re- internship, residency, fellowship, you know, and then you, then you finally get to go be a doctor, and you have to go learn how to be a doctor s- a little more. The patients teach you a lot more than people realize. So I was gonna be an orthopedist. I liked orthopedics. I liked architecture, bones, joints. I thought it was a lot of fun. I just had very little aptitude for what they do. I, I don't-- I, I'm not very g- a good carpenter. I just, you know, I didn't-- just wasn't gonna be a great orthopedist. So then I thought, "I really love cardiology." Rhythm disturbances, all kinds of things. In the 1980s, when I was in medical school , all the new stents and procedures and non- less invasive things than bypass surgery were all coming up. Joint valve replacement. You know, it's really exciting. But I never... and I never took a, a f- a course in rheumatology until I was actually an intern in internal medicine program in Denver, all set to be a cardiologist. And there were 12 of us in the, in the program per year, and s- five of us became rheumatologists because of this one doctor who took us out, a guy named Daryl McCarter. Prob- maybe people who know him, he's retired recently. He would bring us in the office, and we'd see every other patient with him because in between the patients, he would give us an X-ray, say, "I want you to look at this. There's a clue here. See if you can find it." Or, "I want you to look at this pathology slide," or something. "There's a secret, you know, to figure this one out." And I go, "Wow, this is really fun stuff." And once you figured it out, we weren't as good at treating it yet, but we were getting better. We were getting better. So it was the cutting edge and very fertile ground for discovery. So, rheumatologists are called the consult of last resort for a reason. There aren't very many of us. You've usually seen everybody else first, and by the time they-- you see us, we're pretty good at figuring out the rare diseases that are not in other people's board exam. But we're also pretty good at figuring out the common disease that presents in a very strange way, you know? And, and that's what our strength is. So we may... Everybody who sees us who gets diagnosed may not have a rheumatology answer, but we try to get them an answer. And now we're really in the golden age of rheumatology in the last 20 years of really making a difference for so many people. The downside, we don't make a difference for enough people, you know? We, we... That's the problem. So we've got these very motivated doctors out there, eager, and we just need, you know, more. And that's why I became an entrepreneur, because I learned more neurology than I was supposed to know and more sleep physiology than I was supposed to know. You just follow the breadcrumbs, you know? [00:06:17] Lindsey Dinneen: Yeah. Okay, so I know you didn't start out wanting to, or maybe even being interested in being an entrepreneur, but that is the path that you chose, and I would love to hear about that, the company, and what you're all doing. And then also would love to hear about your journey into deciding that this is the next right step for me. [00:06:38] Andrew Holman: Yeah. Well, thanks for asking it. It is a little unusual. So I was actually studying and trying to help patients with fibromyalgia about 30 years ago. And fibromyalgia patients terribly dismissed till they're all making this up. There's not 10 million people that can make anything up and be consistent. I mean, they all say the same thing. So I thought that was nonsense, and I was really thrown into the crowd of, you know, "You're, you're crazy too." And I go, "Well, I'm board certified in crazy." So I w- I was interested in it, and I was irritated that these people were dismissed. And I was around other doctors in Seattle who were similarly that way, which was very, very unusual. It's unusual to find people in the '90s who had an avid interest in that disorder. And so I started doing what rheumatologists are good at, incrementally advancing ideas and therapeutics very carefully, very cautiously. We do a lot of things off-label. When I was-- finished my fellowship in 1992, half the diseases on our board exam had no FDA-approved treatment. We had to do something, right? You couldn't just say, "Well, come back when there's a couple of articles in the New England Journal of Medicine." You, you can't do that, right? People are depending on you. So rheumatologists are particularly good at that, and that's not something most doctors want to do. Most doctors find that very uncomfortable. They're very, very careful people. And, and rheumatologists are careful too, but we take this mission seriously that we need to do something for you. So basically, I was looking at off-label ideas and work on fibromyalgia, and I'll share this with your audience. I was actually pulled up-- pulled in by some senior doctors who said, "We wanna talk with you." And I'd been there about three years as a new doctor. Oh, you know, seem to be doing a good job. Maybe they wanna pat me on the back or something. No, not that. It was actually an intervention, which I had never... I mean, I had no familiarity with what an intervention was. And they said, "Look, we like you. You're a great doc, but you're gonna ruin your reputation if you believe all these people, mostly women And you really need to not take it so seriously or write prescriptions for this c-- this and that." I said, "Well, thank you very much." That's polite. That's not what I was thinking. And I, I... But it prompted me to pull all the charts and say, "You know, I think I'm making some progress here with some ideas here, and let me see if I'm getting fooled and just seeing the people who get better to come back. Let me really honestly look at my performance." And so I pulled about 200 charts. It was my first abstract at the national meeting. And you know what? We were making progress. That had morphed into more progress, following the breadcrumbs, looking at neurology, looking at the autonomic nervous system. So that was about a five-year process. Y-you know, I didn't lose my reputation, obviously. I lecture around the world now. But it led to being very careful about getting clinical evidence if I had a hypothesis. And so we were using the office, and we actually finally did a double-blind prospective study where I bought all the drug myself, had it reformulated, little capsules that, you know, and, and worked with the FDA to get permission to do the study. And that study in fibromyalgia to this day has the highest response rate of any fibromyalgia study for pain that's ever been done. Now, we don't use that treatment anymore. It's 20 years later, we have other things to do. But it did prompt Pharmacia, got bought by Pfizer, I believe, and Boehringer Ingelheim, which co-marketed the drug I was using and reporting on, to pay me $10 million for the patents that I had filed, utility patents. I didn't own the drug. I didn't use it for Parkinson's disease, but I thought there was use in fibromyalgia. So before I told the world, I filed utility patents, and they wanted to exploit that discovery. So did two other pharmaceutical companies, and they had to pay for the privilege of doing it. So at 46, I retired. So I didn't intend to do that, but I do come from a family of lawyers and judges, and so the idea of having a utility patent on a n- a new innovative idea was not a foreign concept to me. [00:10:40] Lindsey Dinneen: Yeah. [00:10:41] Andrew Holman: That is something I teach all young doctors. [00:10:46] Lindsey Dinneen: That is awesome, and I, I was thinking, okay, this is a great segue because first of all, that's an incredible story. Secondly, I, I would be very curious to know exactly that, what is your advice for some of these incredible physicians, great ideas, that are potentially going to end up becoming an entrepreneur just because that's the path that, that is sort of presented to them? What is some of your advice for that? 'Cause that can't just be... you, you had the privilege at least of, of, of knowing and having some background in that, the legal aspects of IP protection and whatnot, but what are some of the things that you tell people? [00:11:22] Andrew Holman: Well, a couple things I would say and I have these conversations often 'cause I really like the younger people coming along. I say, first of all, don't define yourself as an ent- as being an entrepreneur. Make sure you have other things in your life that are more important to you. Now, the investors are not gonna like to hear that. They, they want you to live and die on your, on your company, right? But I'm saying, you know, you don't have to tell the VCs, but have other things that matter more in your life. You still gotta work really hard because you may, you may find that it's really a slog, and it's very long, and it's very hard. But, you know, make sure that, that, that what you-- though is important, your family, you know, your integrity the scientific problem at hand, the patients, you know, they're number one. Make sure we don't lose sight of all that, and do a few things. Go for a walk. Do something for yourself. Something. I do this twenty-four seven for the last 10 years, you know, every day 'cause I love doing it. It does wear you out, though. Even if you make-- even if you're successful with milestones, it does wear you out. But that's what I tell them. I say, "You know, make sure that you take care of yourself a little bit, too." It's kinda like a analogy. What do you do for a pregnant woman who has a, who has a, a lupus? Lupus is terribly dangerous for the fetus and for the mom. Though the worst thing you do to-- for the baby is not take care of the mom. Take care of mom, [00:12:44] Lindsey Dinneen: Mm-hmm. [00:12:45] Andrew Holman: then get the baby delivered. So, you know, everybody's talking about the baby, but take care of mom. That's the most important thing you do for that baby. So that's kinda what I would say. [00:12:54] Lindsey Dinneen: Yeah. Yeah, that's great. I appreciate that. Yeah, that, that makes a lot of sense too. We've been talking, actually it's been a, a bit of a theme too lately in some of the conversations that I've been having with folks, especially leaders, to talk about that identity component and, and be aware that your job isn't the only thing that defines you or needs to. There's a lot more to your life. There's a lot more to who you are. And so also, you know, our identities change over time and how you refer to yourself and th- those are, those are good things. That's growth, that's movement. So, being comfortable with who you are outside of your career. Yeah. [00:13:33] Andrew Holman: The other thing too is, you know, people used to joke 20 years ago that participation mem- medals were like a farce and what. That's the l- that's the last thing I would say to anybody. Give yourself a pat on the back for going out there trying to attack the castle, you know. Give yourself some credit there because a lot of people just wouldn't do it. My middle daughter was a hundred-meter hurdler at Boise State. She's a Division I athlete. There's a lot of sprinters out there that don't wanna get anywhere near that hurdle 'cause it really hurts when you hit it, right? And so half of that was not-- was being brave. So be brave, be brave, you know. My other daughter was a Division I athlete at Rice. She was a h- she was a volleyball player. Yeah. So, yeah. So I, I, I, I watch other people, see how they persevere and, you know, okay, gotta pick yourself up. Gotta go. Gotta get up this morning. Gotta go. [00:14:23] Lindsey Dinneen: That's right. That-- Yeah. [00:14:25] Andrew Holman: Then remember, people are depending on you, not just your investors. I take that so seriously. But the s- the people who have decided that they're gonna hook their wagon to you. [00:14:34] Lindsey Dinneen: Yeah. [00:14:35] Andrew Holman: You know, that's a lot of responsibility. [00:14:37] Lindsey Dinneen: It is. Yeah. [00:14:38] Andrew Holman: Give yourself a little credit that you're stepping up. [00:14:41] Lindsey Dinneen: Yes. Great advice. Yeah. Okay, so all right. So let's talk about your company now. So now you're an entrepreneur, in addition to obviously the rest of who, what makes you, you. But and I know that you're also a clinical professor, and I would love to hear about both of those things if you don't mind sharing. [00:14:59] Andrew Holman: Yeah, sure. So, technically I'm an associate clinical professor at the University of Washington. A, a lot of private docs do, and they participate in helping teach the y-young residents and fellows and so forth. So it's a joy to me. I, I think my job is a job of teaching. I'm constantly talk... I'm not-- I don't see patients anymore, although I do maintain my license in malpractice 'cause I get, I get contacted for the fibromyalgia work I did. So it's, my email's on the papers, right? So I, I don't wanna let that go. People need help. But basically, we're constantly teaching patients, you know. Now, we're listening, hopefully do better and better at that, but then I have to make a case. You know, I'd, the-- I'd like you to try this or that. Why do I wanna do that and so forth. We're constantly, you know... We don't-- It, it sounds too trite to call it selling something. We're not doing that. We're in there with you. We're collaborating. But I have to be, I have to have a reason and be persuasive and all that, so that, that academic teaching part's kind of fun. Now, sometimes I go into the lion's den. I will tell you, it's a little nerve-wracking to give rheumatology grand rounds at Harvard. Yeah, yeah, okay. You know, and the University of Washington, they're a little friendlier. It's my hometown. But Guy's Hospital in London and the Hospital for Special Surgeries, I... My first rheumatology grand rounds came at the HSS in 2009. I get there, I completely bomb. All these famous people are in the front row. I'm... They're, they're just not buying any of this thing we call immunoautonomics and how stress affects the immune system. I'm quoting the NIH. I'm doing everything I... I know how to do it, right? Pathology slides, I'm there. Then I find out the way they pick the speakers is the fellows get to find something interesting, and they pick the speakers, not the not the high mucky-mucks. So the only reason I was there is because the fellows, the young folks, thought, "This is an interesting topic. We'd like to hear more." And it turns out they were 15 years ahead of the rest of the world, because this is the most fascinating topic of how the immune system affects the autonomic nervous system affects the immune system, so it inflames it. [00:17:03] Lindsey Dinneen: Yeah. Oh my gosh. Actually, that is one thing I wanted to talk about, 'cause I, I noticed on your LinkedIn profile there was, you know, a reference to how much stress affects cardiovascular health maybe particularly chronic stress. And I would just love to hear more about that and, and maybe some ways... I know there's like, y- of course you always get your standard, "Here are some things that you could do to lower your stress." But, but from your perspective as a physician who's studied this, I'd love to hear more from you about, okay, how does this affect health, especially cardiovascular health, and then really what are some practical things that we can do? [00:17:39] Andrew Holman: Yeah, let me see what I can do. Now I wish I could fast-forward because we will have some magnificent things in the next five to 10 years based on what's being discovered now. But the bottom line is, stress and pain are awful things, but they have a purpose in the near term. So pain is good because it'll keep you from putting your hand back in the fire, right? Just don't do that again. But chronic pain is terrible and not productive. Stress is the same thing. You wanna get away from the lion. You, you, you need to perform. If your child needs you, whatever, you, you need to perform on it instant. But chronic stress is not productive. The problem with the stress response is it's controlled in the brain by the autonomic nervous system, which is called the ANS, and it's divided into two components, the sympathetic fight or flight, which we all know what that feels like. You know, ooh, scary. And the other is the parasympathetic, which is getting more talk now, which is the opposite, which is related to rest, restorative, sleep, recovery, growth hormone, all these things. And both of these systems are on simultaneously all the time, but they jockey for predominance depending on what the demands are around you, right? So turns out the sympathetic part has a significant negative impact on cardiovascular health, as you might expect, right? If you're driving your car at five thousand RPMs-- now, nobody has a stick shift anymore-- but if you're driving at five thousand RPMs, you're gonna wear down your engine, even if you go at the same speed as someone who has a two thousand RPMs, right? It, it's, it's what's going on inside the hood there is really important. So stress responses chronically do have measurable, tangible, well-published effects on cardiovascular mortality in long prospective studies. So if we had a magic something, we would do something to lower that epinephrine adrenaline response. Unless, of course, you're in the military, where someone's-- you need every heightened, m-- you know, response that you can get to survive. But for the rest of us, it's better that that system does not ramp up and activate. And we all have a different propensity to how powerful it is and how much it turns on, and also how poorly it turns off. So the stress response, we think of it like epinephrine, adrenaline. That's the easiest way to do it. So what you'd wanna do is to make sure this magnificent part of your brain that is your-- does all your housekeeping functions, this autonomic nervous system, the command and control center that you just wanna work, you don't wanna think about it, is not on a turbocharged, right? And there are people I take care of that they were just born that way. A lot of them, by the way. So things like all the wellness opportunities you can think of are, are targeted just to simply calm the autonomic nervous system. Tai chi, meditation, diet, exercise, all these things have been around for thousands of years because of that. That's what they do. And the practitioners will share that with you. I mean, the there are monks that can lower their heart rate, you know, to like, you know, what would seem lethal to the rest of us, right? That's the parasympathetic drive that lowers heart rate, lowers blood pressure. So those wellness opportunities are real. It will be important that you can manage whether the-- what you're doing is working or not. [00:21:04] Lindsey Dinneen: Mm-hmm. [00:21:04] Andrew Holman: Right? And that's where my company comes in. But the other is things like obstructive sleep apnea. You might think heavy guys... See, someone's gonna send me for a sleep study for sure, but they're not gonna send you. Big mistake, because it turns out that fifty-three percent of Japanese women with rheumatoid arthritis have unexpected obstructive sleep apnea. Oops. And, and we were just taught that we wouldn't even check those people. Well, turns out sleep apnea untreated is a major cardiovascular risk factor equal to cigarette smoking, according to the Sleep Heart Health Study in 2004. That's a big deal. And also, we learned in rheumatoid arthritis, getting back to my work, world, that patients with rheumatoid arthritis don't die from joint disease, they die from premature heart disease. They can also get cancers. So why is that? Well, there's been a lot of effort to try to figure that out in the last twenty-five years, and their risk factors for cardiovascular disease are not explained by the Framingham risk factor of hypertension, cholesterol, smoking, and all the things we, we look, see. But nobody looked at sleep apnea. [00:22:15] Lindsey Dinneen: Mm-hmm. [00:22:17] Andrew Holman: The other reason it's so relevant, though, is sleep apnea is a potent sympathetic arousal. It, it-- You struggle to breathe, right? You kind of obstruct. And what part of your brain tells you to breathe? Your autonomic nervous system. Breathe, right? And it stimulates this adrenaline response over and over and over, and it pounds your heart over the years, and it can lead to sudden death and arrhythmias. So there's a, there's a link there. Never miss sleep apnea. The other one is we found in our office and published about restless leg syndrome. You know, people tap their toes in the airport or they kick the covers around at night. It's pretty benign for most people, but it looks like it very well might be a sympathetic arousal, and there may be relevance there. The therapies for that may have relevance to what we're talking about. Again, very off-label. We're not talking about FDA-approved here. But it-- You ask what can you do? The other one that's coming is vagus nerve stimulation. That is FDA-approved now for rheumatoid arthritis, and they're going to other opportunities to, again, to, to increase the parasympathetic and to lower the sympathetic, right? So that background activity doesn't harm you. The autonomic nervous system may be the primary reason that two patients respond differently to the same treatment. What you bring to the table. It's no different than if I have two people coming to me for a back problem. One is five foot three and one is seven foot three. The way their spine is designed makes it a whole lot harder to treat the seven-foot back, right? I'm not surprising anybody here. So there are things that the patients can bring to the table that matter. Here's the irony. Ninety-seven percent of patients with rheumatoid arthritis in a survey in England said that stress affected their disease activity. It's no surprise to them. And sixty-five percent said they thought it predated getting the disease, that it actually contributed to getting it in the first place. And now there's evidence to suggest that may be true. [00:24:17] Lindsey Dinneen: Oh, boy. [00:24:19] Andrew Holman: So we can't miss sleep apnea just out there. We can't miss restless leg. We can't miss Ehlers-Danlos type three hypermobility type where people can... you can't see me here, but my fingers can bend backwards. But it's, it basically it's very, very common, and those people tend to have increased sympathetic activity naturally. [00:24:39] Lindsey Dinneen: Fascinating. [00:24:39] Andrew Holman: So yeah, so we're, we're waking up a little bit to some very important features here of individuals that may help us do better with the diseases they also come in. [00:24:50] Lindsey Dinneen: Yeah. Wow. [00:24:52] Andrew Holman: Sorry, long answer. Sorry, but there's a lot. [00:24:54] Lindsey Dinneen: No, that's great. I appreciate it, and yeah, well, then there you go. Managing stress is critical to, to your health. It's not just a nice to have, like yeah, yeah, kind of thing. Okay. Whew. [00:25:07] Andrew Holman: Good learning. [00:25:08] Lindsey Dinneen: Okay, awesome. Yeah, so, I'm curious... Okay, so, so again, I like, I like looking at guests' LinkedIn profiles and, and learning more about, you know, what makes you tick outside of your career as well, and I noticed some very fun things that you have listed. So we've got creative writing, horsemanship, golf, and vintage passenger rail cars. I feel like this warrants... [00:25:33] Andrew Holman: Yeah, it's called... Yeah, the American Association of Private Railcar Owners. Yeah. I get ribbed a lot for that, but they're a great bunch. There are about --I don't know if I know all the numbers now, but about 75 to 80 vintage cars from the '20s, '30s, '40s, '50s, who tag on the back of Amtrak, and Amtrak drags them around, and you can actually go rent them, stay in them, whatever. And they have a a annual meeting where they just get on a private train, and they go on tracks that you wouldn't go on naturally, like private rails in the, you know, middle of nowhere. So that's what they like to do. And it's just a lot of fun, especially the dome cars. [00:26:12] Lindsey Dinneen: Okay. That's so cool. [00:26:14] Andrew Holman: I've been a handful of times. I've got a lot of friends there. I don't own a car, but boy, I'd sure like to have one. [00:26:19] Lindsey Dinneen: Yeah. Okay. That is so cool. And then how about horsemanship? How did you... Have you been riding horses your whole life, or how did that come about? [00:26:29] Andrew Holman: So I went to a high school called Thatcher School in Ojai, California, where there are 50 in a class, and there was a requirement, this is over 100 years old, this school, that you had to have a horse. And they would say s- that something about the "outside of a horse is good for the inside of a boy," right? I was the last all-male class in 1977. Now young women get to go there too. It's of note that I have 15 people from Thatcher investing as family and friends in, Inmedix. So, th-they that, that's pretty special. But it's a boarding school. I was there for four years. My dad had gone there, so I'd heard of it. But I got a tremendous education. Th-there aren't a lot of prep schools on the West Coast, but there are some. And, and that's where I learned how to ride a horse like riding a bicycle. My sister is a thoroughbred horse trainer for 40 years. She's retired. She had three or four or five horses, a har-- not the fancy kind of stuff at the Derby. But they, you know, get up at 4:00 a.m. and ride, you know, that kind of... Tough life, but she loved horses. So yeah, I, I'm as, I'm more comfortable on a horse than I am around anything, probably. [00:27:34] Lindsey Dinneen: That's so cool. Okay. Well, this has been really fun to, to get to hear your incredible life story so far, and I'm excited to see where the company continues to advance medical technology. So, you know, I really appreciate everything you're doing. But I do want to ask, is there a moment that stands out to you along your career path so far where you just thought, "Wow, I am in the right industry at the right time"? [00:28:02] Andrew Holman: Yeah, I'd, I'd say there probably was. When we unblinded the prospective double-blind study that we did looking at this five-minute next generation heart rate variability, this HRV we got through the FDA last year. When we unblinded the study, and although that's not part of the FDA clearance, it was a very important moment for me because it showed that it predicted a year in advance who would respond to treatment of rheumatoid arthritis with ninety percent sensitivity, ninety-five percent specificity. So I wanna emphasize that is not what it's cleared for. It's cleared as an HRV tool that doctors can use at their discretion. But that study is what you asked me to answer. And when you unlock a study and you see the results, two things happen. One is we were happy that I was on the right track. That was nice. You know, positive study. Your hypothesis is valid. But it completely changed the view of immunology, [00:28:58] Lindsey Dinneen: Hmm. [00:28:59] Andrew Holman: Because we would have a test now that could measure the autonomic nervous system with exquisite precision. Nobody cared except me. About 10 years ago, we were waiting for better biologics, the things on TV, right? They asked, "Ask your doctor if it's good for you." Nobody realizes that they work about twenty-five percent of the time in terms of disease control. That's a big gap, but it looks like it's the brain that monitors inflammation. The inflammation the immune system is not firewalled against everything. The brain c-controls it, and it's not the endocrine so much with cortisol, it's the autonomic that works in milliseconds that, that epinephrine response. So that's a... You know, you're pretty nervous when you un-- when you-- someone tells you, "Okay, here is the results." [00:29:48] Lindsey Dinneen: Yeah. Wow. [00:29:50] Andrew Holman: And, and, and that was it. And then it turned out in 2015, the other moment was when I was going through the airport at Seattle and I saw the cover of of Scientific American, Bioelectric Medicine, Setpoint Medical's vagus nerve stimulation, hacking the the vagus nerve to fix the autonomic nervous system to reduce the burden of rheumatoid arthritis. I go, "Okay, now it's time." We had the patent on it. Okay. Ten years forward, we're where we are now. We're launching in June, and we have a software juggernaut here and a literally a vital sign. So, th-the doctors decide what to do with this, but we've put it in their hands, and it's paid for by insurance. So yeah. [00:30:34] Lindsey Dinneen: Amazing. Well, that's, that's so cool. Congratulations on that. That's fantastic. Okay, so to pivot the conversation a little bit just for fun, [00:30:43] Andrew Holman: Hmm? [00:30:43] Lindsey Dinneen: imagine that you were to be offered a million dollars to teach a master class on anything you want. What would you choose to teach? [00:30:53] Andrew Holman: Well, I, I learned that you've all had professors that didn't probably know as much as they should about a subject, but they thought it was just fun. I would probably stick with what I know. So I would do a master class on fibromyalgia because you can actually treat it. And there's published data, but it's very-- it's not widely known. We will be using Inmedix and autonomic testing to do research to validate and get that problem finally solved and put to bed. And then the other is this thing called immunoautonomics. It, the term-- I made up the term 15 years ago. It's in the medical literature. So that's what I would teach. Teach what I know. [00:31:27] Lindsey Dinneen: I love that. Okay, excellent. And how do you wish to be remembered after you leave this world? [00:31:34] Andrew Holman: Well, I, you know, it all come... I define myself by what the patients, how they do and what they say. It's not about five stars and all that, you know, you know, there's plenty of those. But it's, it's... I made a, a commitment if somebody says anything about me, I made a commitment when I was a rheumatologist with all these mostly young women upset, that I would never leave the room with them crying. Didn't matter how far behind I was, didn't matter. We went through a lot of Kleenex. There's a l- it's devastating to get these diseases when you're a young woman. And they can put that on my tombstone, not to dismiss people. We had a saying in the office, "It's gotta be something." You know? It's, it's always something. Drives me crazy when doctors will say, "Oh, that's nothing." Well, well, first of all, we know it's not nothing. It, it is always something, and there's something that defines your success, and there has to be things that define your failure. So let's figure out what the something is, but let's not argue that there's nothing there. So let's not dismiss people who are frightened and worried, and maybe they don't tell the story as clearly as we'd hope. But you know what? It's not, it's not their fault. They're in distress. It's amazing what people are like after you help them with their chronic pain. [00:32:45] Lindsey Dinneen: Yeah. Yeah. That is really cool and makes so much sense. Yeah. Thank you. Okay, and then final question: what is one thing that makes you smile every time you see or think about it? [00:32:59] Andrew Holman: It's making me smile right now. When I talk to the young fellows that are in their training and they're finishing up, so they've done three years or four years of medicine, three years of internal medicine after that, and then they do three or two, three, four years of rheumatology, and then they're gonna go out, I tell them how jealous I am of what they're gonna see. The, the last, the last 40 years we had these young men mostly coming in with terrible weight loss and immune systems, falling apart, and these strange tumors, and they're dying of, of infections like yeast and candida that, you know, everybody did fine with, and it was HIV, right? It had to be figured out. Now HIV is a chronic disease. It's like diabetes. We had so many people die in the '80s. Hepatitis C was... You'd have liver enzymes up, and it wasn't hepatitis A 'cause we could test for that, and it wasn't hepatitis B 'cause we could test for that. So we just called it non-A, non-B. Literally, that's what we called it. And then that got to be called hepatitis C, right? 'Cause it was too embarrassing to call it n- what it wasn't. And now hepatitis C is curable with antiviral agents in, like, three weeks. I mean... And then the biologics showed up. They're not perfect, but they were a big step. And then this immunoautonomics and, and understanding how pain and sleep and the autonomic nervous system work. I'm just really jealous of what those young clinicians are gonna get to see. [00:34:27] Lindsey Dinneen: Yeah. Yeah, that's really... Yeah, I can see why. But it sounds like you are, you know, keeping, keeping your what, what would they say? Like, toe in the water or something so that you're able to, to watch some of this as well and be a part of that next [00:34:40] Andrew Holman: I feel like I'm a ne- I feel like I'm neck deep and I'm just hoping I don't go down any lower. [00:34:47] Lindsey Dinneen: Fair enough. [00:34:48] Andrew Holman: 'Cause I have to find a way to pay for it. [00:34:50] Lindsey Dinneen: Oh, yeah, yeah, yeah. The details, you know. Yeah, yeah. [00:34:53] Andrew Holman: You got those details, yeah. [00:34:54] Lindsey Dinneen: Yeah. Oh my gosh. Well, this has been an incredible conversation. I really appreciate your time today and sharing your insights and, and stories and, yeah, I'm so excited to see the future of medicine, and I appreciate perspectives of, like yours, where you just, you share a lot of hope and optimism, and you're actively working to change lives for a better world. So, thank you. [00:35:16] Andrew Holman: Yeah, I, I irritate a lot of people with that optimism, but I'm sorry, it's just there. I can't fix it. [00:35:22] Lindsey Dinneen: Brilliant. Well, I love it. It makes my heart happy, so thank you so much again, and I hope you have the best rest of your day. [00:35:31] Andrew Holman: Thank you so much. Thanks for having me. [00:35:32] Lindsey Dinneen: Of course. [00:35:34] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

I have two witnesses for you today. The first is a member of the Big Life Mentoring Group. The leader, Pamela Crim, gave us a PDF that helps us write our God story. It is great because every one of us has had God working in our lives and yet we don't know how to talk about it. This PDF gives us a structure to use to get our story written down. Today's first witness talks about how different her life was 15 years ago to 1 week ago. The second witness is from a member of my prayer group. He sent a prayer request from his brother-in-law. I have included the prayer request and the results of our prayers. Let's begin with the first witness. 15 years ago, I committed suicide- I say I succeeded because I was found by a first responder without life but was resuscitated. Too much pain; I just could not go on another day. 13 years ago I watched my daughter be consumed by Heroin and give premature birth to a baby boy who quickly passed. 12 years ago, knowing I would probably lose my daughter to overdose, I turned her life over to God and stopped interfering with his plan for her. I knew my next contact would be from the police telling me they found her body. This is where it gets crazy! 10 years ago I married the first responder who literally helped revive me through CPR on that night I was found lifeless. He is the best man my kids and I could have ever wished for. 9 years ago, my daughter found recovery through jail, but hey, any recovery is amazing. She was left with a confirmed diagnosis of Hepatitis C, multiple times by multiple doctors, that was likely not anything we could ever afford to treat. I was just grateful she was alive. 8 years ago my daughter gave birth to an amazing, beautiful, healthy girl. The pediatric Hepatologist was on site for the birth, knowing they would have to treat baby and mom. Baby and mom were retested, and no signs that Hep C had ever existed. Drs said it was unexplainable. 1 week ago I sat with my daughter, 9 years recovered, with my newest granddaughter on my lap, watching my 8-year-old granddaughter play softball. None of us should have been sitting there. None of us should be alive, but God kept his promise and created beauty from the ashes. I'm blown away by his love for us and treasure every single day! This is no normal story… It's a great story, and it's a God story. Here is the second witness: I received a text message from my friend John. The message said, “Please pray for my brother-in-law, Alex. He climbed on a ladder to wash the second-floor windows, but the ladder moved because of the water and fell to the ground. He broke his arm and fractured his chin. He is at the hospital right now and would really appreciate some prayers. I sent the prayer request out to the whole prayer group. The next day I received this text message back from John. This message is to let you know the good miracle news of the great power of our lord and the power of intercessional prayer. After a few X-rays and all that the doctors did for my brother-in-law, they determined that the chin fracture wasn't there anymore, and he only needs some kind of Braces to fix his bottom teeth. The arm fracture, they said, is minor, and he is gonna be in a sling for a month. It's all black-and-blue bruises in his body, and he's going home tomorrow!!! Yeeeahhh … PRAISE The Lord. Please share this testimony like the holy Bible says. Thank you very much, and I love you guys mucho! Thank you both for sharing your testimony. When we share the amazing things God is doing in our lives, other people may start to see how God is working in theirs. When we hear of God doing miraculous things, it builds our faith. We all need that. We live in a world where you need to see it to believe it. So, the more we can hear about the supernatural happening, the more it builds our trust and faith that it could happen for us. We believe; Lord, help our unbelief! www.findingtruenorthcoaching.comCLICK HERE TO DONATECLICK HERE to sign up for Mentoring CLICK HERE to sign up for Daily "Word from the Lord" emailsCLICK HERE to sign up for my newsletter & receive a free audio training about inviting Jesus into your daily lifeCLICK HERE to buy my book Total Trust in God's Safe Embrace

Send us Fan MailHost Mighty Fine and guest Paige Colburn-Hargis explore how to make the case for dedicating community health benefit resources to a drowning prevention and water safety program. Together, they discuss strategies for demonstrating community need, aligning injury and violence prevention efforts with hospital priorities, and securing support from hospital leadership. Host: Mighty Fine, MPH, CHES  Mighty Fine is the Associate Executive Director of the American Public Health Association (APHA), where he provides leadership across initiatives that advance public health science, policy and systems change. In this role, he helps shape APHA's strategic direction while leading efforts to design, implement, and evaluate programs that strengthen public health practice and improve health outcomes. He also provides technical assistance, consultation, and evidence-to-practice translation to local, state, and national partners. As a trained social epidemiologist, Mighty brings a population health perspective to some of the most pressing issues in public health, with particular attention to how social, structural, and environmental conditions shape health outcomes and inequities. His expertise spans injury and violence prevention, family health, HIV/AIDS, Hepatitis C, social policy, and chronic disease prevention. Through his work, he is committed not only to preventing disease and injury, but also to shaping community conditions that promote collective well-being. Mighty's leadership extends beyond program strategy and implementation as he represents APHA across a variety of initiatives that inform public health policy, strengthen practice, and elevate the field nationally. He brings a practice-informed perspective to these efforts, drawing on his experience as both a social epidemiologist and health educator to help shape the future of public health. He is also committed to highlighting public health as a meaningful career pathway, particularly for emerging professionals seeking to make an impact through community-centered public health practice. Through university guest lectures, national conference presentations, and other professional engagements, he continues to share knowledge, foster learning, and contribute to the development of the field. Having lived and worked in rural and urban environments, Mighty credits this empirical insight with anchoring his understanding of systematic levers of oppression. Thus, a core part of his work has focused on addressing the structures that serve as pillars of disadvantage. He has built expertise in the social determinants of health and brings a social justice perspective to the assessment and prevention of public health issues. Mighty holds a Bachelor of Science in Public Health from Rutgers University and a Master of Public Health from Yale University, with concentrations in Social and Behavioral Sciences and Chronic Disease Epidemiology. He is also a Certified Health Education Specialist (CHES), credentialed by the National Commission for Health Education Credentialing. In his free time, Mighty enjoys traveling, spending time with loved ones and attending concerts. Guest Information: Paige Colburn-HargisPaige Colburn-Hargis Injury Prevention Program Coordinator, Scripps Memorial Hospital, La Jolla Paige Colburn-Hargis serves as the Injury Prevention Community Outreach Coordinator for Scripps Memorial Hospital La Jolla, a Level I Trauma Center. She brings more than a decade of experience leading injury prevention initiatives across hospital, community, and national platforms. Paige is past chair of the Injury Prevention Committee for the Trauma Center Association of America and is an appointed member of the Aging and Independence Services Advisory Council for San Diego County. She has led regional coalitions, developed nationally recognized fall-prevention initiatives and projects, and created impactful public health campaigns, including the My Grey Matterz helmet safety initiative. She also coordinates the San Diego County Lifeguard Advisory Committee, a multi-agency coalition focused on improving prehospital care, enhancing interagency collaboration, and strengthening injury prevention efforts along San Diego's coastline. Most recently, she was appointed as a Sector Leader to the Binge and Underage Drinking (BUDI) Alcohol Policy Panel Advisory Board, further supporting her commitment to equity-driven, community-based prevention strategies. Paige's passion for injury prevention is deeply rooted in lived experience: as the parent of a child who sustained a severe TBI while skateboarding without a helmet, she has a profound appreciation for the importance of trauma-informed care, community education, and prevention-focused systems. This personal journey continues to shape her work and advocacy across the trauma care continuum. She is the recipient of the 2023 Women of Impact Award for her leadership in e-bike and micromobility safety education and recently received a Proclamation in honor of National Bike Safety Month from the County of San Diego. She remains a dedicated advocate for systems collaboration, policy change, and trauma prevention nationwide. 

Why can someone accused of a serious crime be released on bail — and why might the detectives investigating them sometimes be pleased when that happens?Former Scottish detectives Tom Wood and Simon McLean take an inside look at bail and remand: what bail actually means, how the system has changed during their careers, and the factors courts consider when deciding whether an accused person should remain at liberty or be held in custody pending trial.They discuss the days when bail could literally mean putting up money for someone's release, the continuing use of bail bonds in the United States, and the underlying principle in Scots law that an accused person has not yet been convicted and should normally remain at liberty unless there is sufficient reason to keep them in custody.Tom and Simon examine the practical reasons bail may be opposed, including:the seriousness of the alleged offence;the risk of absconding;further offending;interference with witnesses;destruction or concealment of evidence;and obstruction of justice.Tom also reveals a less obvious reality from major investigations: detectives could sometimes be quite pleased when a person facing a serious charge was granted bail. Keeping someone in custody starts strict legal timetables and can put enormous pressure on investigators trying to assemble a complex case.The conversation also explores how Scottish bail law developed through precedent and stated cases, changes to the modern bail test, the use of remand, and the police practice of releasing accused people on undertakings to appear at court.Simon and Tom also refer to the recent Simon Levy case while discussing the risks associated with offending while on bail.Later, the conversation moves to policing and drugs, as Tom discusses news he had read about advances in hepatitis C treatment. That prompts both detectives to recall the very real dangers faced by officers searching people who used injected drugs — including uncapped needles, needle-stick injuries and the routine question: “Do you have any sharps? Do you have any spikes?”It's an aspect of criminal justice that everyone has heard of, but one that is often very different from the version portrayed on television.Real cases. Real detectives. Real talk.Suggested Chapters00:00 — Cold open: why detectives might actually want bail00:52 — What bail really means01:28 — When bail meant money03:08 — Liberty before trial and the presumption of bail04:17 — When bail can be opposed04:34 — Simon Levy and offending while on bail05:04 — Why accused people are remanded06:10 — Why bail can help a murder investigation06:54 — Common law, precedent and stated cases10:20 — Modern bail rules and reducing remand11:55 — What police put before prosecutors12:40 — Undertakings and release from custody13:55 — Lord Wheatley and the war on drugs14:54 — Hepatitis C and the risks faced by drug-squad officers18:11 — ClosingAbout Crime Time Inc.Season 5 of Crime Time Inc. broadens its reach across two sides of the Atlantic.This season features cases from Scotland and across the wider UK — rooted in real investigative experience — alongside deep dives into some of the most infamous murder cases in American history.Hosted by former detectives Simon and Tom, with experience in both the UK and the United States, including time working alongside the FBI, the show strips away sensationalism to explain how crime and justice really work.Two crime worlds. One podcast.New episodes released regularly throughout the season.Our Website: https://crimetimeinc.com/If you like this show please leave a review. It really helps us.Please help us improve our Podcast by completing this survey.http://bit.ly/crimetimeinc-survey Hosted on Acast. See acast.com/privacy for more information.

This week we talk about the liver, viral infections, and the NHS.We also discuss blood scandals, needle usage, and Nobel Prizes.Recommended Book: A World Appears by Michael PollanTranscriptThe term “hepatitis” refers to the inflammation of the liver, which can result from all kinds of things, including environmental toxins, the consumption of alcohol, or autoimmune diseases. It can also result from viral infections, and the most prominent liver-inflaming viruses are called viral hepatitis.There are five types of viral hepatitis, A, B, C, D, and E, and each of these viruses are distinct, not part of the same viral family, they're just similarly named because they impact the same organ.Hepatitis A and E are primarily spread through contaminated food and water, and generally resolve on their own, untreated, and cause relatively mild symptoms. Hepatitis B and C are spread through blood and other bodily fluids, and can linger in a host's body for decades before even showing symptoms. Hepatitis D is a parasite of Hepatitis B, and thus only infects people who carry Hepatitis B.Now again, these are all different conditions that just happen to inflame the liver, so impact and treatment also vary quite a lot. As I mentioned, A and E generally present with mild symptoms and tend to go away on their own, while B and C can stick around a long time. There's a vaccine for B, but no cure; you can treat it, but that treatment involves suppressing it, and keeping it suppressed, forever. Hep C, in contrast, is curable, and has been since 2014 using what are called direct-acting antiviral pills, but these pills, which are taken for 8 to 12 weeks, are expensive—ranging from $22-95k without insurance, though that price is often reduced substantially for those with insurance, down to as low as $5. This category of drug coverage is often rejected by insurance companies, though, in part because they're so expensive, that expense the result of little competition in this space; few companies make this type of drug, so those that do can charge more or less whatever they like.Some people with Hepatitis C clear it on their own; about 30% of people who contract it, in fact, clear it within a few months, medication-free. Which is good, because our understanding of this virus is relatively new. Up until 1989, Hep C didn't even have its own name: it was established as its own thing, not Hep A and not Hep B, back in the 1970s, and doctors knew that something that wasn't those two viruses, that was being spread by transfusions, was causing hepatitis symptoms, but they didn't know any real specifics, so they just called it “non-A, non-B hepatitis,” and that name stuck for more than a decade.In 1989 the virus was cloned using molecular techniques (as opposed to simply growing the virus, which wasn't proving fruitful in trying to isolate and identify the thing), and the folks who managed that cloning, and the person who later proved that the genome they cloned, alone, caused the disease, received a Nobel Prize in Medicine for their efforts in 2020.By 1991, antibody tests were available for Hep C, and many countries began screening donated blood for this virus, to ensure it wasn't working its way into their blood supply.And one instance of that screening process, or I suppose, an event that led up to mass screening, and the consequences that followed, are what I'd like to talk about today. The UK's efforts in trying to eliminate Hep C, and England's recently announced near-success in that pursuit.—Hepatitis C is an RNA virus with high genetic variability that makes developing a reliable vaccine difficult. And though somewhere between a quarter and a third of all cases clear on their own, those that don't clear on their own become chronic, lying in wait for twenty to thirty years, slowly accumulating fibrosis—thick scar tissue in the liver—which eventually results in cirrhosis, which means a liver that's so heavily scarred that the organ is no longer fully functional and the damage is permanent. From there, infected people often experience liver failure or hepatocellular (huh-pah-toe) carcinoma, liver cancer.So this virus is a sleeper, and unless it's caught by accident somewhere along the way, it slowly causes damage over time until the damage is too severe to reverse. About 80% of people who have it don't know they have it, and in some parts of the world medical injections are the most common transmitter, but in higher-income areas, it's usually transmitted by injectable drugs.Pre-2014 treatments for Hep C were pretty horrible, involving a combination antiviral therapy called pegylated interferon plus ribavirin that was injected weekly for six months to a year, and this was terribly tolerated by pretty much everyone, causing anemia, depression, and flu-like symptoms for the duration. It also only cured about 50% of people who received the full treatment, and a lot of people had to stop because it caused such ridiculous side effects.Another antiviral called Sofosbuvir (so-FAS-buh-vir), which kept Hep C from replicating in its host, hit the market in late-2013, and that led to a series of direct-acting antivirals that reduced the treatment period dramatically, allowing most people, 95%, to cure their Hep C entirely by taking generally well-tolerated pills for 8 to 12 weeks.These pills were staggeringly expensive from the get-go, with an entire treatment course initially costing about $84,000, or $1,000 a pill. This led to rationing, and saving these pills for the worst-impacted people who already had severe liver damage. There were also pretty stringent requirements attached to their distribution, including that people who received them could no longer drink alcohol, because it was considered a waste to give these crazy expensive, liver-saving drugs to people who would just go and hurt their liver more, anyway.In the UK, the demand for this treatment type was different than in most other countries, in large part because of something that happened back in the 1970s and 80s.The UK's publicly funded healthcare system, the NHS, was in the midst of a shortage of clotting factor, which are plasma proteins and ions that help blood clot and which are used for medical purposes. So they imported a bunch of plasma products from the US, and those products were sourced from the blood of paid donors—and that donor pool included prisoners and people who used injectable drugs. Just one Hep C contaminated blood donation could contaminate an entire batch of blood, and remember, they only started screening the blood supply for Hep C in 1991, and they didn't start treating their blood supply for Hep C until a little before that, 1985, so this was well before they had any idea what was in those blood products they were importing and administering.Consequently, between 1970 and the early 1990s, more than 30,000 NHS patients received transfusions or other blood product treatments contaminated with Hep B, Hep C, or HIV, and about a tenth of those people, around 3,000 patients, have since died of those conditions.The UK government leaned on denial and a refusal to look into the details of this for years, but in 2017 it announced an independent public inquiry into the matter, and in May of 2024, that inquiry concluded that this whole scandal was avoidable, that patients were knowingly exposed to “unacceptable risks,” and that there was a big cover up by government officials, doctors, and other people working with the NHS.As of mid-2026, only a little over 3,200 people of the more than 18,500 who registered claims, demanding compensation from the government because they were impacted by this scandal, have been paid out. The expected total expense for the UK government is on the order of 12.8 billion pounds, but a lot of people who are probably due a payout, and who are in poor and deteriorating health as a consequence of all this, don't yet have a sense of when they'll receive their payment.Back in 2016, before all that came to a head, the UK set itself an aggressive goal: to eliminate Hep C by the WHO's 2030 target, or before. It then ran a competitive tender for antivirals, inviting medical suppliers to submit competing bids, resulting in the largest single medicine procurement program in the NHS' history. The pharmaceutical companies that won their bids were also obliged, as part of the agreement, to help fund efforts to identify undiagnosed but infected patients, in addition to supplying antiviral pills, and this combination of investment and application led to the deployment of new tests and scanning machines, free postal test kits, the hiring of specialists, and services that focused on prisons and drug users.The impact of all this has been significant: a more than 61% decline in infections from 2015 to 2024, nearly half of all drug users with Hep C had cleared the virus in that time, and deaths from Hep C are down 36% over the past decade.The WHO treatment-coverage target—the percentage of people who are diagnosed getting treatment—was 80%, and England has hit 81.5%, which was recently announced to much fanfare. It hasn't yet hit the diagnosis target, however, which is to diagnose 90% of people who are estimated to have Hep C; they've hit 84.6%, which is still quite a lot of progress, even if they're not yet where they'd like to be. That's all based on models, of course, as are the assumed number of infections among people who use injectable drugs, which is also a spot where England is currently flagging; there's no centralized system in England to monitor needle and syringe provisions, and reinfection rates are around 8.8 per 100 person-years among people who had injected within three years of receiving treatment, and that rate is even higher for people who have ever been to prison, around 9.4 per 100.What that means in practice is that the English government overall has done a pretty astounding and effective job at negotiating their relationships with pharma companies and getting detection on track at that scale, but on more ground-level issues that are, interestingly, a lot cheaper to implement, but at times more politically complicated because of public sentiment about drug use and drug users, they're doing a lot less well—and important to note here is that these outcomes vary a bit across the four programs being run across the UK. Scotland and Wales are doing relatively better and worse in some regards compared to England, for instance.Also worth noting here that while England is broadly doing a great job with Hep C diagnosis and treatment, they aren't the first to achieve those WHO-set goals: Egypt reached Gold tier status according to the WHO's Hep C guidelines in October of 2023, at that point having diagnosed 87% of people who have the virus, and treating 93% of those who were diagnosed. They managed to cut incidence of the virus by 97% in just 8 years, leaning on a system of high-yield testing—they tested more than 60 million people during those 8 years—alongside a production scheme that included local manufacturing of antivirals, making them more available and affordable.All of which are generally good signs about where Hep C testing and treatment is going, at least in these regions. And it paints a optimistic picture for other countries that might want to replicate some of what's working within their own borders.Show Noteshttps://www.bbc.com/news/articles/c75gk620r22ohttps://en.wikipedia.org/wiki/Infected_blood_scandal_in_the_United_Kingdomhttps://en.wikipedia.org/wiki/Hepatitis_Chttps://en.wikipedia.org/wiki/Viral_hepatitishttps://en.wikipedia.org/wiki/Hepatitis_Bhttps://www.healthline.com/health/hepatitis-c/treatment-costshttps://www.who.int/news-room/fact-sheets/detail/hepatitis-chttps://publichealthscotland.scot/publications/surveillance-of-hepatitis-c-in-scotland/surveillance-of-hepatitis-c-in-scotland-progress-on-elimination-of-hepatitis-c-as-a-major-public-health-concern-2025-update/https://www.emro.who.int/media/news/egypt-becomes-the-first-country-to-achieve-who-validation-on-the-path-to-elimination-of-hepatitis-c.htmlhttps://www.gov.uk/government/publications/hepatitis-c-in-england-and-the-uk/hepatitis-c-in-england-2025https://www.england.nhs.uk/2026/08/100000-people-receive-treatment-to-cure-deadly-hep-c-virus-on-nhs-in-just-ten-years/https://www.hepctrust.org.uk/blog/2019/04/hepatitis-c-trust-welcomes-elimination-deal-hepatitis-c-and-calls-government-backed/https://commonslibrary.parliament.uk/research-briefings/cbp-10099/https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis/reports/global-hepatitis-report-2026 This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

Pequeños negocios podrán financiar renovación de vehículos Ofrecen pruebas gratuitas para detectar VIHIrán ofrece 30 mil dólares por capturar a un militar estadounidenseMás información en nuestro podcast#grc

Coming up, Australian researchers have found a new way to help prevent malaria. How have they done it? Also, the UK is "leading the world" in efforts to eliminate hepatitis C, a designer vest that could protect our astronauts from space radiation, and how a new aerogel-based toothpaste can tackle tooth sensitivity. Like this podcast? Please help us by supporting the Naked Scientists

Trump calls on Iran to pay compensation for the deaths and injuries of Americans in conflicts allegedly linked to Tehran, The Washington Post reports that Trump was snuck out of Turkey in a catering container, Russia frees an ailing U.S. Marine after four years in detention, Syria sentences al-Assad to death in absentia, Republican senators release a batch of Fauci's COVID-19 text messages, Turkey approves a conditional pardon bill for thousands of PKK members, Lebanon Indicts ex-central bank chief for Salameh for alleged embezzlement, the U.S. Justice Department sends polling monitors to in Minnesota's primaries, a U.S. court rejects social media companies' bids to block thousands of youth addiction suits, and the U.K. says it's close to eliminating Hepatitis C. Sources: Verity.News

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

https://rumble.com/user/TheCultureWarshttps://x.com/NewsK365https://buymeacoffee.com/courtpresshttps://www.youtube.com/@NewsK365Email: newsk365@protonmail.com

Crece el río Lerma, habitantes piden auxilioAseguran 200 kilos de metanfetamina en Sonora Las autoridades no me intimidan: Evo Morales #grc

Today I'm chatting with Nurse Amber, a board-certified women's health nurse practitioner, to discuss sexual health and STIs. We cover the prevalence and stigma of herpes, common STIs like chlamydia and gonorrhea, testing frequency, and prevention methods including PrEP and DoxyPEP. Our conversation also addresses female health concerns such as UTIs, bacterial vaginosis, and pelvic floor health, as well as men's sexual health topics. Nurse Amber emphasizes open communication, regular testing, and finding a sex-positive healthcare provider.Understanding Herpes Transmission (00:02:11)Discussion on HSV-1 and HSV-2, how both can be transmitted genitally or orally, and why blood testing has limited utility.Most Common STIs (00:08:18)Chlamydia, gonorrhea, and trichomonas are identified as the most common STIs seen in clinical practice, with chlamydia being most frequent.Symptoms of Common STIs (00:08:50)A description of potential STI symptoms in people with vaginas and penises, noting that 50% of cases are asymptomatic.What is Trichomonas? (00:10:02)An explanation of trichomonas, a common parasitic STI that often causes no symptoms but can cause severe inflammation.Long-Term Risks of Untreated STIs (00:11:50)Untreated bacterial STIs can lead to serious complications like Pelvic Inflammatory Disease (PID), chronic pain, and impaired fertility.STI Incubation Periods (00:14:39)Genital STIs are detectable 1-2 weeks post-exposure, while blood-borne infections like HIV and syphilis can take 1-3 months.How to Disclose an STI to a Partner (00:15:53)Advice on having a direct conversation with partners about a positive STI test and the need for mutual treatment.STI Testing Frequency (00:17:19)Recommendations for testing frequency based on sexual activity, ranging from every 6-12 months to every 2-3 months for active individuals. PrEP and DoxyPEP Explained (00:21:49)An overview of PrEP for HIV prevention and DoxyPEP, a post-exposure prophylaxis to reduce the risk of bacterial STIs.Syphilis is Not Gone (00:26:47)Syphilis, known as "the great pretender," is still prevalent and can have sneaky symptoms, making regular screening important.The Current State of HIV (00:29:00)HIV is now a highly treatable chronic condition, and transmission rates are much lower than for other STIs like Hepatitis C.What to Ask For at the Gynecologist (00:31:59)Clarifying that a pelvic exam is not always a Pap smear and what specific STI tests patients should request.The Importance of Triple Testing (00:37:23)Why testing genital, oral, and rectal sites is crucial for a comprehensive screening, as infections can exist in one area.Myth-Busting: Partner Testing (00:42:04)Debunking the myth that if one partner tests negative, the other is also clear. Each person needs individual testing.Vaginal Health and Hygiene (00:44:01)Advice on maintaining vaginal health, emphasizing that vaginas are self-cleaning and harsh soaps or douching should be avoided.Squirting and Prolapse (00:50:31)Explaining that squirting is largely urine and discussing bladder prolapse, a common condition that can cause stress incontinence.Pelvic Floor Health (00:54:39)How to maintain pelvic floor health through exercises like Pilates and yoga, which can improve sex and prevent incontinence.Hormone Replacement Therapy (HRT) (00:58:16)A discussion on the benefits and considerations of HRT for perimenopausal symptoms, cautioning against unproven testing methods.When Men Should See a Doctor (01:02:54)An overview of symptoms like itching, discharge, pain, or sores that should prompt a person with a penis to seek medical care.Finding a Sex-Positive Provider (01:17:29)The importance of finding a healthcare provider you can be open with about your sexual health for accurate testing and treatment.Follow The Open Bedroom:https://www.instagram.com/theopenbedroompodcast/

Hepatitis zählt zu den gefährlichsten Infektionskrankheiten weltweit – und bleibt doch oft lange unentdeckt. Im Hörgang der MedUni Graz erklärt die Hepatologin Vanessa Stadlbauer-Köllner, warum insbesondere Hepatitis B und C noch immer ein großes Gesundheitsproblem darstellen. Viele Betroffene wissen nichts von ihrer Infektion, weil die Erkrankung oft jahrelang ohne klare Symptome verläuft. Dabei können die Folgen schwerwiegend sein: Leberzirrhose, Leberkrebs und andere Komplikationen. Die Expertin spricht über aktuelle Entwicklungen bei Prävention und Therapie, über wirksame Impfungen gegen Hepatitis A und B sowie über die nahezu vollständige Heilbarkeit von Hepatitis C. Zudem zeigt sie, warum flächendeckende Tests und bessere Gesundheitskommunikation entscheidend sind. Eine Folge über eine stille Krankheit, die jeden treffen kann – und über die Chancen, sie rechtzeitig zu erkennen und zu verhindern.

Q-Bank: https://www.patreon.com/highyieldfamilymedicineIntro (0:35),Liver Function Tests (1:42),Hepatitis A (4:33),Hepatitis B (6:02),Hepatitis C (8:44),MASLD (10:51),Alcoholic Liver Disease (12:11),Autoimmune Hepatitis (13:29),Acetaminophen Toxicity (14:53),Wilson Disease (15:55),Hemochromatosis (17:28),Cirrhosis (18:48),Ascites (20:59),Esophageal Varices (23:36),Hepatic Encephalopathy (24:54),Hepatorenal Syndrome (26:31),Hepatocellular Carcinoma Screening (27:52),Practice Questions (28:39)

The Addicted Mind Podcast: How a Little Becomes a Lot with Eric ZimmerIn this episode, Duane welcomes back Eric Zimmer, host of The One You Feed podcast, behavior coach, and author of the new book, How a Little Becomes a Lot: The Art of Small Changes for a More Meaningful Life.Eric shares his profound journey from being a homeless heroin addict facing 50 years in prison to building a deeply meaningful life in long-term recovery. Together, Duane and Eric break down why massive life transformations don't happen overnight, but are instead built on thousands of microscopic daily decisions. They explore how to navigate behavioral "choice points," overcome the trap of perfectionism, and beautifully balance the duality of acceptance and change.Key Takeaways from the EpisodeThe Fallacy of the "Big Moment": While "moments of clarity" are real and pivotal, they only matter if they are backed up by small, daily actions over time.Change is a Skill: Struggling to change a habit is not a character flaw or a sign of laziness; it is a skill set that must be practiced and learned.The Autopilot Pitfall: Many of our worst habits occur completely outside of our conscious awareness. Learning to slow down and introduce deliberation is key to making better choices.The 80% Rule: Except for active substance addiction, striving for 80% consistency in life (exercise, meditation, healthy eating) protects you from the self-sabotage of perfectionism.Puzzles Over Problems: Shifting your perspective from "I have a problem" to "I have a puzzle" opens the door to curiosity and solutions rather than shame.In-Depth Discussion TopicsAt 24 years old, Eric was a homeless heroin addict, weighing 100 pounds, jaundiced from Hepatitis C, and facing severe prison time. When he finally agreed to long-term treatment, it wasn't his first attempt. Eric explains how his previous "failures" to stay clean were actually an essential part of his learning process.Mastering "Choice Points"A choice point is that exact split-second where you either move toward your best self or fall back into old behaviors. Eric notes that relying purely on willpower at a choice point is a losing game. Instead, behavior change requires two distinct layers:Structural Elements: This includes your support system, clear protocols, accountability partners, and removing triggers from your environment.In-the-Moment Skills: This involves recognizing self-doubt, slowing down the urge, and learning how to "trick" yourself into taking action by shrinking the task (e.g., just putting on your running shoes to walk to the mailbox)."The music producer Quincy Jones has this line, and I love it. He says, 'I don't have problems, I have puzzles.' There's a shift in there that's really important, because a puzzle has a solution. It has an answer. We just haven't figured it out yet." — Eric ZimmerMoving Beyond the Self-Improvement ProjectThe episode wraps up with a deep dive into the final chapters of Eric's book, focusing on presence and radical acceptance. While it seems counterintuitive for a book about behavior change to end on "allowing everything to be exactly as it is," Eric explains that treating your life as a non-stop self-improvement project strips away contentment. True healing happens when we can skillfully change what we can, while holding space for our pain, low moods, and current realities without judgment.Framework: The 80% Rule vs. The Perfection MindsetThe Perfection MindsetThe 80% Consistency FrameworkViews every slip-up as a total failure.Views slip-ups as temporary data points and "puzzle pieces."Relies heavily on high motivation and intense willpower.Relies on structural support, habits, and reducing friction.Leads to burnout, self-sabotage, and quitting.Leads to long-term, sustainable lifestyle changes."If I can't do it perfectly, why bother?""If I can just hit 80% consistency over a year, I'm winning."Resources Mentioned in this EpisodeEric Zimmer's Website: oneyoufeed.net (Find his podcast, behavior coaching program, and new book)Eric's Book:How a Little Becomes a Lot: The Art of Small Changes for a More Meaningful Life – A Guide to Lasting Transformation Through Behavioral Science and WisdomThe Addicted Mind Website: theaddictedmind.comFollow and Review: We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review” then a quick line with your favorite part of the episode. It only takes a second and it helps spread the word about the podcast.Supporting Resources:If you live in California and are looking for counseling or therapy please check out Novus Mindful Life Counseling and Recovery CenterNovusMindfulLife.comWe want to hear from you. Leave us a message or ask us a question: https://www.speakpipe.com/addictedmindDisclaimerSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In Episode 136 of DC EKG, Joe Grogan hosts Tom Barker, a top drug-pricing attorney at Foley Hoag and former acting general counsel of Health and Human Services (HHS) under the Bush administration. Tom helped implement Medicare Part D and now advises drugmakers and policymakers on complex pricing issues. The episode traces 20 years of policy: what went right with Part D, what the Inflation Reduction Act (IRA) did, and what effective policy should look like.Tom explains that Part D's success rested on three pillars: private plans only, limited government control over benefit design, and a non-interference clause barring the government from intervening in negotiations among plans, pharmacies, and manufacturers. Competition worked and premiums stayed low, until the government asserted more control and weakened those pillars. The IRA, he argues, was a 16-year Democratic effort to repeal non-interference, creating price controls disguised as negotiations.The Trump administration has taken a different tack, focusing not on the IRA but on MFN and Globe Guard models pegged to other developed countries. Tom also breaks down the 340B program, now the country's second-largest expenditure program, and the fight between manufacturers and covered entities over contract pharmacies.His prescription is simple: let competition work. Speed FDA approval of generics and biosimilars, and trust the marketplace over price controls. He points to hepatitis C, where prices fell sharply once competition entered.In This ConversationThe three pillars that made Part D successful for 20 yearsHow non-interference kept government from setting drug pricesThe IRA as a 16-year Democratic push to repeal non-interferenceWhy Tom calls the IRA price controls disguised as negotiationsThe Trump administration's focus on MFN and Globe Guard pricing340B and the battle between manufacturers and covered entitiesThe Chevron repeal's impact on drug pricing lawHRSA's proposed rebate model and ongoing 340B litigationWhy effective policy means competition, not controlsTom's work helping North Korean defectors and refugeesKey Timestamps1:51 Tom's background at HHS and CMS2:30 The three pillars of Part D's success5:10 Why Democrats wanted to repeal non-interference5:55 Ted Kennedy's compromise and bipartisan votes11:38 The IRA as a 16-year repeal attempt12:03 What the IRA changed in Part D15:02 IRA negotiations vs. real negotiations16:25 How the excise tax makes it no real negotiation21:32 Trump's focus on MFN and Globe Guard25:37 340B's history back to 199128:45 340B as the second-biggest expenditure program29:30 Manufacturer vs. covered-entity acrimony33:18 The Chevron repeal's impact on pricing34:54 HRSA's rebate model, the next step on 340B35:40 The lawsuit over "patient" in 340B38:18 Tom's advice: let competition work39:30 Hepatitis C: competition drives prices down40:34 Competition for gene therapies and CRISPR41:36 Tom's work for North Korean defectors44:49 Sponsoring Free North Korea RadioMedicare Part D, drug pricing policy, Inflation Reduction Act, non-interference clause, 340B program, MFN pricing, Globe Guard pricing, pharmacy benefit managers, covered entities, contract pharmacies, biosimilars, generics, federal drug pricing, government price controls, Tom BarkerAbout the GuestTom Barker is a partner at Foley Hoag in Washington, DC, and one of the country's top drug pricing attorneys. He served as acting general counsel of HHS and chief legal officer at CMS under the Bush administration, where he helped implement Part D from its inception. He is now a go-to expert on drug pricing, and helps North Korean defectors navigate US immigration law.Podcast: DC EKG with Joe Grogan Episode: 136 Guest: Tom Barker Sponsor: Survivors for Solutions - https://survivorsforsolutions.org Executive Producer: John "CZ" Czwartacki, DC EKG Podcast Producer: Stay on Course Studios - https://www.stayoncourse.studio

This episode covers hepatitis C.Notes: https://zerotofinals.com/paediatrics/infectiousdisease/hepc/Questions: https://members.zerotofinals.com/Books: https://zerotofinals.com/books/The audio in the episode was expertly edited by Harry Watchman.

It's Monday, May 18. Here are today's top stories around Central Indiana. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org and follow us on social media to get local news every day. WFYI News Now is hosted by Barb Anguiano and produced by Zach Bundy. Subscribe wherever you get your podcasts.

New York State's Hepatitis C Dashboard shows that in 2023, 4,783 people were newly diagnosed with HCV in the state, an 8% decrease from 2022. Incidence also decreased, with the rate of new HCV infections dropping from 4.0 to 3.6 per 100,000 population among adult New Yorkers. Despite these gains, progress towards elimination has been stalled by reliance on a multi-step diagnostic algorithm to confirm viremia. In populations with the highest risk of infection – including people who inject drugs – testing and treatment are often inaccessible due to barriers along the care cascade. On June 27, 2024, the U.S. Food and Drug Administration authorized the first point-of-care (POC) HCV RNA test that can be performed where a person receives care, like an outpatient clinic or mobile unit. The availability of a POC HCV RNA testing, which can provide a qualitative results in 60 minutes, unlocks New York's ability to integrate a test-and-treat approach where a person can be tested for HCV, and if positive for HCV RNA, be linked to care and potentially receive treatment during the same health care visit. To achieve elimination goals, simplified care that engaged people who inject drugs is essential, and single encounter testing and treatment offers a new tool to significantly expand access, decrease time from diagnosis to treatment and increase the number of New Yorkers who are treated for HCV. Today's episode will focus on this new diagnostic tool and its potential impact on HCV elimination across New York. Related Content:  New York State Department of Health Clinical Guidelines Program, Hepatitis C Virus Screening, Testing, and Diagnosis in Adults (January 2023): https://www.hivguidelines.org/guideline/hcv-testing/?mycollection=hepatitis-care New York State Department of Health Hepatitis C Dashboard: https://hcvdashboardny.org/ New York State Department of Health, Frequently Asked Questions for Hepatitis C Point of Care Diagnostic Testing (June 2025): https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/providers/docs/poc_faq.pdf Erie County Medical Center's Center for Hepatology Care (La Bodega): https://medicine.buffalo.edu/news_and_events/news/2020/04/martinez-bodega-hepatology-clinic-10699.html U.S. Food and Drug Administration News Release, FDA Permits Marketing of First Point-of-Care Hepatitis C RNA Test (June 2024): https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-point-care-hepatitis-c-rna-test MacIsaac MB, et al. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility. Int J Drug Policy. 2024 March:125:104317. doi:10.1016/j.drugpo.2024.104317. Point-of-care HCV RNA testing how to video: https://vimeo.com/1172653335?fl=ip&fe=ec

Episode 223: Oncogenic Viruses Introduction Mehr: Hi everyone, welcome back to the Rio Bravo qweek podcast. Back by popular demand is Me, Mehr Boparai a third-year medical student at COMP-NW. Here with me is Jeremy Pan from COMP who is also a third-year medical student. How are you doing Jeremy? Jeremy: I'm doing great Mehr.Thanks for the kind intro; we had a fun time this morning doing street medicine and had some practice giving Toradol injections and wound dressings. So excited to be back for another podcast episode this afternoon! Mehr: This week, we are moving away from bacteria and antibiotics and diving deeper into cancer-causing viruses. Jeremy: Yes, and if you are interested at all in public health, this is one of those areas where medicine overlaps with public health in a really tangible way. I think one of the most underappreciated aspects of this topic is that we have vaccines that can prevent many of these cancers. If you told someone 50 years ago we'd be vaccinating against cancer, they probably wouldn't believe you! It's amazing to see how far medicine has come. How viruses cause cancer: Jeremy: Before jumping into specific viruses, I always think having a mechanism-based framework makes everything stick better. Mehr: Right, because they don't all cause cancer the same way. Medicine can never be easy huh? Jeremy: Yea…this career really is just a lifetime of discovery. So just to start, in broad terms, we can think of three main buckets of how viruses can cause cancer: Direct oncogenesis where viral proteins interfere with tumor suppressors like P53 and Rb. We will go over their specific mechanisms a little later in the discussion. Mehr:  Chronic inflammation where viruses cause repeated injury through production of reactive oxygen species. They also increase the chance of mutation through repeated DNA replication, leading to cancer.  Jeremy: Immune evasion or suppression leads to decreased tumor surveillance. What this means essentially is that our immune system is constantly removing abnormal cells before they become cancerous. This is completed by CD8 T cells and natural killer, or NK, cells. CD8 T cells recognize abnormal peptides presented on Major Histocompatibility Complex, or MHC, class I molecules and induce apoptosis in those cells. Mehr: And NK cells step in when cells decide to stop expressing MHC I, which abnormal cells like to hide to avoid being caught. So just to reiterate, there are two layers to dissect here: if a cell looks suspicious with an abnormal MHC, CD8 T-cells kill them. If the abnormal cell decides to hide its MHC, then the NK cell will kill it instead. Jeremy: So, for the final big picture, we can think of oncogenic viruses as either disabling tumor suppression, causing chronic damage over time through inflammation, and weakening the immune system's ability to catch cancer in time before it develops. HPV Mehr: Let's start with one of the most common viruses afflicting our population – Human Papilloma Virus otherwise known as HPV.  Jeremy: Right, this notorious virus is probably the most clinically impactful oncogenic virus. The key players HPV utilizes are proteins E6 and E7. Mehr: Right! E6 binds to and inhibits p53, which normally acts to induce cell cycle arrest, and E7 inhibits Rb, which normally acts as a tumor suppressor gene that inhibits the G1 to S phase transition in a normal cell cycle. Jeremy: So essentially, we are losing both apoptosis and losing cell cycle control at the same time. What is interesting about HPV is that persistent infection, not just exposure to the virus, is what drives cancer risk.  Mehr: Exactly, most HPV infections clear on their own, but the ones that persist are the problem. Clinically, many end up being asymptomatic. However, for high-risk infections, we can see genital warts that can itch, feel tender, or cause abnormal vaginal bleeding and discharge. Patients are sometimes not able to have a vaginal delivery because of the warts that are present along their genital tract. We can also see warts on the hands and fingers or plantar surface of our feet. Jeremy: Another interesting point is that we are also seeing a shift where there are more cases of oropharyngeal cancers in younger, non-smoking patients. This is why if we see an abnormal neck lymph node or persistent sore throat after swallowing in a young patient, HPV should definitely be on the differential.  Mehr: Screening is very important as well! We typically discover high-risk HPV infections through routine Pap smears and other HPV specific tests through DNA PCR and RNA tests. We also encourage vaccination for effective prevention of both genital warts and high-risk HPV-related cancers. There was also a study in Scotland where there were zero cases of HPV in adults who received the vaccine between 12-13 years of age! Which is crazy!  EBV HBV & HCV Mehr: Now let's shift to viruses that affect the liver, Hepatitis B virus and Hepatitis C virus. Jeremy: Both are strongly associated with hepatocellular carcinoma, but they actually get there in slightlydifferent ways. Mehr: Right. Hepatitis B is a DNA virus that can integrate directly into the host genome, which can disrupttumor suppressor genes and promote oncogenesis. Jeremy: Whereas Hepatitis C is an RNA virus, so it doesn't integrate into the host genome. Instead, it causes chronic inflammation Over time, that leads to repeated cycles of hepatocyte injury and regeneration, along withoxidative stress from reactive oxygen species, which increases the risk of DNA mutations. Mehr: One really important clinical pearl is that Hep B can actually cause hepatocellular carcinoma evenwithout cirrhosis. Whereas with Hep C, the pathway is usually chronic inflammation → fibrosis → cirrhosis → dysplasia→ cancer.  Jeremy: So, screening becomes really important for both of these viruses. For high-risk patients—like those with chronic hepatitis or cirrhosis—we typically dosurveillance with liver ultrasound every 6 months, sometimes with alpha-fetoprotein levels to see if it is elevated. Mehr: From a prevention standpoint, the Hep B vaccine is a huge win. It significantly reduces the risk ofhepatocellular carcinoma. For Hep C, we don't have a vaccine, but direct-acting antivirals can actually cure the infection andreduce long-term cancer risk, which is why we screen between ages 18-79  nowadays. Global Hep B and C account for 65% of all HCC cases! So, it makes sense that primary care itself is increasing the treatment of Hep C cases as well since it is easier to prescribe and that you want to be treated ASAP.  Jeremy: Yea, the ability to treat Hep C is so beneficial to population health. Now let's say you have a patient who develops hepatocellular carcinoma, options can include surgicalresection, liver transplantation, local therapies, or systemic treatments depending on stage.  Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!  __________________________________ References: Barry H. C. (2024). Scottish Screening: No Cases of Invasive Cervical Cancer in Women Who Received at Least One Dose of Bivalent HPV Vaccine at 12 or 13 Years of Age. American family physician, 110(2), 201–202. https://pubmed.ncbi.nlm.nih.gov/39172683/ Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

One of the most common arguments you hear from company executives racing to develop super-intelligent AI is that it will cure cancer. It's an incredibly powerful and seductive promise.  If superintelligent AI really can cure cancer, then anyone who stands in the way of it, anyone who wants to slow it down — even because of its serious risks — is essentially letting people die. In fact, the biggest risk would be going too slowly. But what if a superintelligent AI isn't actually capable of solving cancer in the way it's been described? What if we're being sold a false promise to justify a dangerous race? That's exactly what our guest this week argues is happening. Dr. Emilia Javorsky is a physician, public health researcher, and director of the Futures Program at the Future of Life Institute. She's worked across scientific research, clinical trials, tech startups, and AI policy.   Emilia recently wrote a paper titled “How AI Can and Can't Cure Cancer,” in which she argues that the promise of superintelligence curing cancer falls apart under scrutiny.  Emilia lost a parent to cancer, so her criticism of this promise comes from a place of real concern, not cynicism. It also comes from her belief that AI can be really revolutionary for medicine, if we build it the right way. Your Undivided Attention is produced by the Center for Humane Technology. Follow us on X: @HumaneTech_ and subscribe to our Substack.RECOMMENDED MEDIA How AI Can and Can't Cure Cancer by Emilia JavorskyThe Emperor of All Maladies by Siddhartha Mukherjee RECOMMENDED YUA EPISODES Decoding Our DNA: How AI Supercharges Medical Breakthroughs and Biological Threats with Kevin Esvelt Forever Chemicals, Forever Consequences: What PFAS Teaches Us About AI Big Food, Big Tech and Big AI with Michael MossCLARIFICATIONS: Emilia's claim that “the doubling rate of medical knowledge has gone from 50 years in the 1950s down to 73 days” comes from an oft-cited 2011 paper from the NIH. However, this paper does not include any methodology for arriving at this claim. Emilia stated that we have yet to cure any complex, chronic disease in humans. However, we have been able to cure Hepatitis C, which is considered a complex infectious disease, and we have managed to effectively cure some types of Leukemia Correction: Tristan incorrectly paraphrased a quote from Charlie Munger about incentives. The actual quote is “The basic rule of incentives is you get what you were owed for. So if you have a dumb incentive system, you get dumb outcomes."     Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

PODCAST LAS NOTICIAS CON CALLE DE 23 DE ABRIL DE 2026 - Conflicto de Irán aprieta, USA obliga a 31 barcos a virar - Fox News 6 meses cogería limpiar el estrecho de Hormuz de minas y otras - Fox NewsRivera Schatz versus jefe de la policía y federal en destaque por sargento ascendido - El Nuevo Día  Dos iglesias en fuego en Adjuntas, iglesia Manatial de Vida y luego en Parroquia San Joaquín - Policía Israel y Líbano se atacan mutuamente - Semafor Senado jura que no persigue a Sagardía, que no quiere sus planillas, sino las informativas - El Nuevo Día Confirman han aumentado los abortos en PR desde que se revocó el caso de Roe v. Wade - WSKN Alcalde de San Juan suelta contra La Junta de Planificación y advierte de reforma de permisos - El Nuevo Día  Péptidos son lo nuevo en el mundo de la medicina y wellness - Axios Molesta JGo porque debaten en Legislatura el presupuesto sin tener un proyecto de ella, pero dice que su proyecto espera por junta y reforma contributiva - El Vocero Cerrados portones UPR mientras se reúnen y piden renuncia de presidencia o se van a huelga - El Vocero First Medical en problemas otra vez, médicos y proveedores advierten de años de impagos - Metro Adelantan juicio contra CDobleta por asesinato de policía - El Vocero Policía tendría 800 agentes menos para el 2027 - El Vocero Casos de Hepatitis C en la cárcel siguen fuera de control pero solo 2% de la población ha sido evaluada - Metro Irán cierra Hormuz, EEUU intercepta dos supertanqueros iraníes Hegseth bota al Secretario de la Marina, John Phelan Tesla promete gastar $25,000 millones en IA y robótica este año.  LOS DATOS DEL DÍABrent: $101.91/barril (+3.30%) — futuros al día de hoy en $104.02Diésel wholesale (EEUU): $3.93/galónS&P 500: 7,137.90 (+1.05%) — récordDow Jones: 49,490.03 (+0.69%) — récordBono 10Y del Tesoro: 4.32%Euro/USD: 1.1733Gas natural (Henry Hub): $2.70/MMBtuTasa hipotecaria 30Y: 6.22%#universalinsurance #incluyeauspicio 

Sheinbaum confirma saldo blanco tras incendio en Dos BocasSalud recomienda prueba de Hepatitis C a mayores de 18 añosCuba acusa a EU de presionar contra cooperación médicaMás información en nuestro Podcast#grc

A new, rapid Hepatitis C test developed by Northwestern University scientists could change the future of Hepatitis C care by delivering faster diagnosis and treatments for a disease that is estimated to impact 50 million people around the world. The research behind this new test, which was built on the DASH (Diagnostic Analyzer for Specific Hybridization) Rapid PCR system developed at Northwestern University was published in the Journal of Infectious Diseases. In this episode, Claudia Hawkins, MD, MPH, explains this study and the impact this test could have on the global effort to eliminate Hepatitis C. 

Interview with Jocelyn Young, DO

There are fears reluctance about a new needle exchange service in the South Island may cause a rise in Hepatitis C and HIV cases. Rachel Graham reports.

This Week speaks to members of Transfusion Positive, who were caught up in the Hepatitis C contamination crisis in the 1990s. We then hear from Cliona O'Farrelly, Professor for Comparative Immunology at Trinity College Dublin

Self-care podcast exploring Why The Healing Mentality Matters, Importance of Addressing Root Causes & Steps to Addressing Root Cause Healing with Autumn McLees. TOPICS:: ** Why The Healing Mentality Matters (09:57). ** Importance of Addressing Root Causes (18:42). ** Steps to Addressing Root Cause Healing (29:32).   NOTES:: Show notes: amberapproved.ca/podcast/649 Leave me a review at amberapproved.ca/review Email me at info@amberapproved.ca   Subscribe to newsletter: https://amber-romaniuk.mykajabi.com/newsletter-sign-up    SHOW LINKS: Click below to schedule a 30 minute Complimentary Body Freedom Consultation https://amberapproved.ca/body-freedom-consultation/  Take my free Emotional Eating Quiz here: http://amberapproved.ca/emotional-eating-quiz Listen to Episode 291 about what it's like to work with me here: http://amberapproved.ca/podcast/291/ Follow me on Instagram www.instagram.com/amberromaniuk Youtube Channel: https://www.youtube.com/@amberromaniuk/    ABOUT MY GUEST: Autumn McLees challenges the status quo, equipping women to explore holistic alternative paths to wellness. After overcoming a life-altering autoimmune disease naturally, she's now pioneering her way on an unbeaten path that few, if any, have attempted when battling Hepatitis C.   Autumn is fervently dedicated to challenging traditional practices in healthcare, the food industry, dentistry, childbirth, and beyond. Having witnessed the effectiveness of holistic health approaches, she actively promotes awareness and education in these areas.   Autumn spearheads a top-rated podcast, "Know Better | Do Better," dedicated to advocating for holistic health awareness. As a certified high-performance coach and multifaceted entrepreneur, Autumn has earned recognition through awards, TV and radio appearances, magazine features, news articles, and multiple certifications. For nearly 9 years, Autumn has been the driving force behind a multimillion dollar wellness enterprise, and she is celebrated as a top achiever in her field.   F️REEBIE Clean Swap Guide: https://bit.ly/44EGv6b    Website: https://www.autumnmclees.com/ ️"Know Better | Do Better" Podcast Facebook:  https://www.facebook.com/autumn.mclees TikTok: https://www.tiktok.com/@autumn.mclees?_t=8jGMp83lS5G&_r=1 Instagram: https://www.instagram.com/autumn.mclees?igsh=MzRlODBiNWFlZA== MY PARTNERS: HERBAL FACE FOOD Stubborn eczema, red spots, aging spots, or acne on your face, chest, arms, or back from hormones or hard water damage? I have something SO amazing for you. Our mineral-heavy water started impacting my skin the moment we moved, and I had never experienced eczema or skin issues in my life. Hard water can strip natural oils, disrupt the microbiome, and weaken the skin barrier — leaving you inflamed, reactive, and stuck in flare-ups. That's exactly what happened to my neck, and within almost two weeks of using Herbal Face Food, my eczema is almost gone. This stuff is legit — and I only share my favorite things that actually work. Their formulas are made with ultra-potent, organic, whole-plant botanicals rich in antioxidants, polyphenols, and phytonutrients that calm inflammation, rebuild the skin barrier, and fight visible signs of aging instead of masking symptoms. The Cure is their most targeted antioxidant treatment designed to visibly improve stubborn concerns like eczema, melasma, rosacea, scarring, sun damage, and deeper signs of aging. The Cream is a deeply hydrating, ultra-potent botanical moisturizer that firms, smooths, strengthens the skin barrier, and helps reduce fine lines and wrinkles. The Soap gently cleanses without stripping, using powerful plant concentrates to protect, nourish, and support healthy, youthful-looking skin on both the face and body. If your skin has been struggling from hormones, environmental stress, hard water damage, or premature aging, I'm sharing exactly what I'm using and why it's working. Shop through my link in the show notes or visit https://herbalfacefood.com/?ref=AMBER88 and use code AMBER88 at checkout for 30% off your entire order.   MY PARTNERS: DEEP MARINE COLLAGEN By calming the immune system and nourishing the tissues of your joints, skin, gut, hair follicles and nail beds DeepMarine Collagen works from the inside out to produce Pain-Free Joints, Glowing Skin, Thicker Hair, Stronger Nails and a Healthy Gut. Canadian Listeners Use AMBER20 to receive 20% off all regular priced items by visiting deepmarine.ca or click the link https://deepmarine.ca/discount/AMBER20 to have the discount automatically applied to your order. Free Single Serve Sachets with select purchases while supplies last.   USA Listeners You can find DeepMarine Collagen on Amazon.com. Discounts will automatically be applied to select purchases.

Send a textIn this episode Charles & Lyn share their feelings about the decision by the Australian Human Rights Commission's decision to deny an inquiry into how tens of thousands of Australians impacted by tainted blood transfusions and tainted blood treatments could end up being abandoned.  Show links. Former Labor Health minister Neal Blewett says evidence that he is bisexual or gay is “scuttlebutt”  https://static.wixstatic.com/media/ddd792_2e7e1e141f4e41549717a2e224bc3544~mv2.jpgStatement by Charles MacKenzie to Infected Blood Inquiry (final 5 pages feature my appeal on behalf of Australia to inquiry chair) https://www.infectedbloodinquiry.org.uk/sites/default/files/2021-12-16%20WS/2021-12-16%20WS/WITN3939001%20-%20Written%20statement%20of%20Charles%20Mackenzie%20-%2015%20May%202020.pdfTimeline of discrimination by tax payer funded Hepatitis C groups against tainted blood victims. https://ddd792de-b24d-47fe-8177-91b7438b0894.usrfiles.com/ugd/ddd792_4ac055e13e0e43df9787d08f8f345c8f.pdfPurchase a Make Accountability Happen Again cap here https://joinhighadventure.com.au/patriot-cap/Support the petition for a Royal Commission of inquiry into the Australian Red Cross/CSL Infected Blood Scandal here https://www.infectedbloodaustralia.com/registration

Pati Chapoy y Karina Velasco, hija de Raúl Velasco, protagonizan un insólito reencuentro para sostener una charla más que reveladora.Pati la conoce prácticamente desde que su madre Dorle Velasco la llevaba en el vientre y ella fue a vivir a casa de Raúl para estar al pendiente del parto debido a los constantes viajes del periodista y conductor.Así que de la mano de Pati, Karina aborda desde sus inicios como comunicadora, hasta su fallido matrimonio y por supuesto la irremediable muerte de su famoso padre, luego de haber logrado alargar su vida gracias a un trasplante de hígado a que lo obligó la Hepatitis C que contrajo en una trasfusión de sangre.¿Cómo resolvió semejante duelo? Al responder a la pregunta de Pati, Karina relata la odisea que emprendió desde entonces para reencontrar su camino, convirtiéndose en chef, meditadora, estudiosa de la sexualidad humana e incluso en "poliamorosa" y escritora.Una conversación que fluye con la confianza de quienes se saben no sólo cercanas, sino familia y que es digna de verse porque nada es lo que parece.

Feb. 9, 2026- We highlight what the state is doing, and could be doing, to realize its goal of eliminating hepatitis C transition by 2030. Our guests are Shirley Toro, president and CEO of the National Black Leadership Commission, and Michael Selick, director of Capacity and Community Mobilization at National Harm Reduction Coalition.

This two-part episode of Buffalo HealthCast explores Hepatitis C treatment in Buffalo and in global contexts. In part one, family nurse practitioner and recent MPH graduate Sean Owen talks with guest host Jennifer Foster of the Office of Global Health Initiatives about hepatitis c: what it is, how it's treated, barriers to care, and global efforts to eliminate the virus. Owen talks about his long-running work in Rochester specializing in drug user health, harm reduction, and treatment and prevention of hepatitis C and HIV, along with his recent MPH field training experiences addressing hepatitis C under the supervision of Dr. Anthony Martinez at his clinic La Bodega at the Erie County Medical Center.In part two of this episode, Sean Owen talks to Scott Springer, a physician assistant at La Bodega. Owen and Springer discuss La Bodega's unique model of treatment and holistic care, which has contributed to great success in treating and curing hepatitis C among western New York patients. They also explore reasons why hepatitis C elimination efforts are unique in different parts of the country and different parts of the world. Read (and watch) more about the work at La Bodega: https://medicine.buffalo.edu/news_and_events/news/2020/04/martinez-bodega-hepatology-clinic-10699.htmlhttps://www.cbsnews.com/news/elminate-hepatitis-c-clinic-treatment/Follow us!Official WebpageBuzzsproutSpotifyApple PodcastsYoutubeInstagramFacebookTwitter

Send us a textAs When Humanitarians Kill gathers momentum, Charles and Lyn uncover a disturbing truth: two official inquiries into Australia's tainted blood disaster, the 1991 HIV inquiry and the 2004 hepatitis C inquiry, were quietly derailed. In this episode, they reveal how a small number of well placed gatecrashers intervened, sabotaging accountability and denying victims justice.Show links ‘An alliance of bias timeline'of government funded Hepatitis C groups discriminating against infected blood victims: Before and during the Senate Affairs ReferencesCommittee into hepatitis C and blood supply in Australia 2004 https://ddd792de-b24d-47fe-8177-91b7438b0894.usrfiles.com/ugd/ddd792_4ac055e13e0e43df9787d08f8f345c8f.pdfInquiry crasher Stuart Loveday of Hepatitis NSW lecturing tainted blood victims. https://www.youtube.com/watch?v=DZbIu5Rh7zgProfessor Arthur Bloomhttps://www.bbc.com/news/uk-wales-686247981990 Australian Red Cross telling blood donors found to have the deadly virus hepatitis C that they my continue to donate blood for a process known as ‘plasma fractionation' which is how haemophilia treatments were made.  https://static.wixstatic.com/media/ddd792_6c6046b9c92240f2b3df0c08d4e3db91~mv2.jpgCharles MacKenzie's submission to the Senate inquiry into hepatitis C and the Australian blood supply that he forced in 2004https://www.infectedbloodaustralia.com/_files/ugd/efbdad_895236b193ec408791159e72c47fc122.pdfA former manager of the Hepatitis Council whistleblows about discrimination against tainted blood victims here https://www.infectedbloodaustralia.com/_files/ugd/efbdad_b647814ebfa54607a31265ff034aed61.pdfBe part of making justice happen and purchase a Make Accountability Happen Again cap here https://joinhighadventure.com.au/patriot-cap/Support a Royal Commission of inquiry into the Australian Red Cross/CSL Infected Blood Scandal here https://www.infectedbloodaustralia.com/registration

The Chancellor announced dozens of changes in the Budget that will affect the money in your pocket from wages and energy bills to savings. Many of them won't happen for some time - years in some cases - so we look at the more imminent tax changes. That will include the freezing of tax thresholds that will see higher taxes for many and changes to the Cash ISA limits.A "bewildering system" of benefits - that's how the author of a new report has described the plight of tens of thousands of unpaid carers who were thrown into debt because of the overpayment of Carer's Allowance. This week an independent review was published that's been a year in the making. It started because carers had been working but had unwittingly slipped over the amount they're able to earn before losing their Carer's Allowance - a payment they're entitled to if they care for someone for over 35 hours a week, leaving them in debt to the government. Paul Lewis interviews the author of the report Liz Sayce, who has told Money Box the government must implement her recommendations "at pace".And, the families of thousands of people who were infected with HIV and Hepatitis C by the NHS when it used contaminated blood in the 1970s and 80s will not have to pay tax on the compensation many of them are still waiting for. That commitment came from Rachel Reeves in the Budget, after Money Box reported on a campaign to ensure those relatives weren't subject to inheritance tax bills of tens of even hundreds of thousands of pounds.Presenter: Paul Lewis Reporters: Dan Whitworth and Jo Krasner Researcher: Eimear Devlin Editor: Jess Quayle Senior News Editor: Sara Wadeson(First broadcast 12pm Saturday 29th November 2025)

Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008

'Buenos días, Javi y Mar' informa que este jueves 30 de octubre se debate la obesidad en las Islas Canarias, con un 23% de adultos y un 35% de niños afectados, y el gobierno solicita declararla enfermedad crónica. También se analizan los precios de los alimentos en octubre, con una subida del IPC al 3% y el precio de una docena de huevos a 3,14€. Se comenta la fuerte lluvia en Sevilla y Huelva, con 100 litros por metro cuadrado en Sevilla. La noticia de unos monos escapados en Mississippi, infectados con Hepatitis C y COVID-19, causa preocupación. Se destaca la canción "Todo Contigo" de Álvaro de Luna. En CADENA 100, se debate que las personas que agradecen con la mano a los conductores son más positivas, empáticas y pacientes, y se clasifican los tipos de peatones. Se escucha "Moves Like Jagger" de Maroon 5 ft. Christina Aguilera. Se mencionan las calorías que se queman viendo películas de miedo. Pink interpreta "Just Like a Pill". En 'Buenos días, Javi y Mar', se habla sobre la ...

Hurricane Melissa makes second landfall in Cuba after lashing Jamaica with catastrophic flooding, brutal winds. Governor Newsom sues Trump Administration for illegally withholding SNAP food benefits. Chad Scary Movie Countdown #3. Turkey to discipline referees after uncovering mass betting scandal. New details revealed in NBA betting scandal. One-Hit Wonder Wednesday. Texas attorney general sues Tylenol company over autism claims. Lab monkeys infected with herpes and Hepatitis C escape following truck crash. Toronto outlasts Dodgers to even World Series. 

On today's episode of the MY House Podcast Isaac talks with Dr. Kira England from the Alaska Department of Health! Isaac and Dr. England talk about risk factors for the Hepatitis C Virus, pathways to treatment and the community's role in helping combat the spread of Hepatitis C among vulnerable populations.

Dr. Morse Q&A - Polycystic Ovaries - Urethral Polyp - Hepatitis C - Boils - Cysts #791 00:00:00 - Intro - New Alcohol-Free Tinctures 00:03:58 - Hypothyroidism - Low Libido - Polycystic Ovaries - Urethral Polyp -Hepatitis C 00:37:20 - Fruitarian OMAD - Fasting Diet 00:43:15 - Bladder Infection 00:53:04 - Body Pain - Hyperthyroidism 01:15:47 - Boils - Cysts 00:03:58 - Hypothyroidism - Low Libido - Polycystic Ovaries - Urethral Polyp -Hepatitis C - Hashimoto's  What should I take for hormonal balance and stress? 00:37:20 - Fruitarian OMAD - Fasting Diet Would it be possible to live on a One Meal A Day (OMAD) Fruitarian Diet with daily fasting, and still get enough nutrients to thrive through life? 00:43:15 - Bladder Infection I've had a chronic bladder infection for 7 months now. 00:53:04 - Body Pain - Hyperthyroidism I live in a chronic state of constant pain every single day. 01:15:47 - Boils - Cysts I've been dealing with boils and cysts for 6 years, mostly in the pubic area, sometimes the groin too.

LAS NOTICIAS CON CALLE DE 23 DE JULIO DE 2025 - Comienza proceso para sacar a LUMA, pero justo cuando sale que el contrato que firmó el gobierno con los dueños de Genera no cuadra - El Vocero Playas llenas de E Coli: Sixto Escobar en San Juan, Vacía Talega en Loíza, Lugana de Condado en San Juan, Tropical Beach en Naguabo No quieren sacar a la gente de Punta Santiago para traer un mega proyecto - El Vocero DACO demanda por enseres dañados, tanto Cámara y Senado se unen a demanda - El Vocero Aparece en aparente suicidio médico ginecólogo que iban a acusar por agresión sexual - Primera HoraQuitar el IVU a medicamentos over the counter quitaría 200 millones al gobierno y 18 a los municipios, evalúan medida - El Vocero Se dispara dramáticamente las apuestas en tragamonedas, suben 50 años para 362 millones total - El Vocero Llega casa Kikuet al aeropuerto SJU - El Nuevo Día Van a sus vistas para regularizar su vida en PR y terminan deportados - El Nuevo DíaNo va apoyo PPD a Constitucional de Status, alcaldes PPD dice que no se unen a eso - El Nuevo DíaOtro alcalde busca ama de llaves y no consigue personal - El Nuevo Día Turista se declara culpable de prender fuego en Cabo Rojo - Primera Hora Más casos de Hepatitis C en PR - Primera Hora Caso de Audrinix se le vira a Justicia tras video, pero fiscalía dice que falta info para poder saber lo que realmente pasó - Primera HoraTrump llega a acuerdo con Japón para tarifas de 15% incluyendo carros - Bloomberg Si estás cansado de pagar de más por servicios que no usas ni necesitas, eshora de cambiarte a Liberty.Los planes ilimitados multi-línea Liberty Mix te permiten escoger y pagar solo por lo quenecesita cada línea, con más data de alta velocidad y cero cargos escondidos.Estos planes han sido diseñados con flexibilidad en mente, ofreciéndote un servicio quese ajusta a tus necesidades, y también a tu bolsillo.Visita tu tienda Liberty más cercana hoy y escoge el plan que mejor se ajusta a ti.Liberty, contigo siempre.Incluye auspicio

Emblematic of capitalist corporations, investment bank Goldman Sachs asks a revealing question that shows the evils of capitalism: ‘Is curing patients a sustainable business model?' Nicole Roussell and Professor Richard Wolff discuss the unhealthy effects of the profit drive and huge profits in the pharmaceutical industry, using Hepatitis C treatments as an example, and how the math would work with industry profit no longer built in. Professor Richard Wolff is an author & co-founder of the organization Democracy at Work. You can find his work at rdwolff.com.Join the The Socialist Program community at https://www.patreon.com/TheSocialistProgram to get exclusive content and help keep this show on the air.